RMTG (Regenerative Medical Technology Group) Current Deferred Taxes Liabilities: $ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerative Medical Technology Group Current Deferred Taxes Liabilities?

Regenerative Medical Technology Group RMTG +5.28% Current Deferred Taxes Liabilities is $ Mil as of Jun. 2026. The stock has 3 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Regenerative Medical Technology Group's current deferred tax liabilities for the quarter that ended in Jun. 2026 was $ Mil.

Regenerative Medical Technology Group Current Deferred Taxes Liabilities Related Terms

Regenerative Medical Technology Group Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Regenerative Medical Technology Group's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerative Medical Technology Group Current Deferred Taxes Liabilities Chart

Regenerative Medical Technology Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only - - - - -

Regenerative Medical Technology Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
What does a Current Deferred Taxes Liabilities of $ Mil mean?
Regenerative Medical Technology Group (RMTG) has a Current Deferred Taxes Liabilities of $ Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Regenerative Medical Technology Group and its competitors.
Is Regenerative Medical Technology Group's Current Deferred Taxes Liabilities too high?
Regenerative Medical Technology Group's current Current Deferred Taxes Liabilities is $ Mil.
How does Regenerative Medical Technology Group's Current Deferred Taxes Liabilities compare to BZYR and CLSDQ?
Regenerative Medical Technology Group's Current Deferred Taxes Liabilities of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Regenerative Medical Technology Group and its competitors. Regenerative Medical Technology Group's current Current Deferred Taxes Liabilities is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Fairly Valued. The stock's GF Value™ is $0.08, compared to a current price of $0.08 — trading 1% below its estimated fair value. The current Current Deferred Taxes Liabilities is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Current Deferred Taxes Liabilities is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerative Medical Technology Group Business Description

Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.